Accolade Inc (NASDAQ:ACCD) stock fell 1.49% (As on October 9, 11:49:05 AM UTC-4, Source: Google Finance) after the company reported a narrower-than-expected loss and strong margin growth for the fiscal Q2 2025. Cash, cash equivalents, and marketable securities totaled more than $234 million at the end of the second fiscal quarter. The company generated positive free cash flow of approximately $3.1 million during the quarter. ACCD faces challenges in managing the timing of operating expenses, which have been pushed to the second half of the fiscal year. The company is experiencing pressure from employers for more rigorous ROI guarantees due to rising healthcare costs. About a third of the B2B contracts are up for renewal annually, with retention rates expected to be 90% or above.

Meanwhile, trends like GLP-1s drive demand for advocacy and primary care, as they require navigation in complex care situations. The company’s ability to offer bundled services, including primary care and advocacy, makes us unique and positively impacts the win rate. The company see strong demand across all segments, including enterprise, health plans, and government. Deployment timeframes vary, especially in the health plan space, but demand remains robust across our core platforms.

ACCD in the second quarter of FY 25 has reported the adjusted loss per share of 30 cents, beating the analysts’ estimates for the adjusted loss per share of 44 cents. The company had reported the adjusted revenue growth of 10 percent to $106.4 million in the second quarter of FY 25, beating the analysts’ estimates for revenue of $105 million. Usage-based revenue was about 32% of total revenue, consistent with prior quarters. It comes from EMO, VPC, and direct-to-consumer segments, with a shift from PMPM to usage-based contracts contributing to growth.

For Q3 2025, Accolade forecasts revenue to be between $104 million and $107 million, missing the average analyst estimate of $110.2 million. The company projects Q3 FY 23 Adjusted EBITDA loss to be between $3 million and $5 million

The company also reaffirmed its FY2025 revenue guidance of $460 million to $475 million, compared to the consensus projection of $467 million. It still expects adjusted EBITDA between $15 million and $20 million, compared to the analyst estimate of $16.1 million. The company is facing challenges in managing the timing of operating expenses, which have been pushed to the second half of the fiscal year.